statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gossamer Bio (GOSS) Receives a Buy from Piper Sandler

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Gossamer Bio (GOSS Research Report) today and set a price target of $15.00. The c...

Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says

Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets...

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Collaborates With Italian Drugmaker Chiesi To Advance Lung Health Solutions Worldwide

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

Gossamer Bio, Inc. (Gossamer) (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension...

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine

Gossamer Bio assumed with an Outperform at Wedbush

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

Volume	703,805.00
52-Wk High	$1.60
52-Wk Low	$0.4525

GOSS Gossamer Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals